New Therapeutic Agents Marketed in 2017: Part 1

Activity Preview

Seven new therapeutic agents marketed in the United States in early 2017 are considered in this first part of a series: ocrelizumab, safinamide mesylate, edaravone, valbenazine tosylate, deutetrabenazine, crisaborole, and dupilumab. Indications, mechanisms of action, and information on dosage and administration for these new agents are reviewed, as are the most important pharmacokinetic properties, adverse events, and other risks and precautions. The new drugs are compared with older drugs marketed for the same indications, and advantages and disadvantages are identified.

Learning Objectives: 

At the completion of this activity, the pharmacist will be able to:

1. Identify the new therapeutic agents that are considered and explain their appropriate use.
2. Identify the indications and mechanisms of action of the new agents.
3. Identify the most important adverse events and other risks of the new therapeutic agents.
4. State the route of administration for each new drug and the most important considerations regarding dosage and administration.
5. Compare the new therapeutic agents with older medications to which they are most similar in properties and/or use, and identify the most important advantages and disadvantages for the new drugs.

At the completion of this activity, the pharmacy technician will be able to:

1. Identify the new therapeutic agents that are considered and explain their appropriate use.
2. Identify the indications and mechanisms of action of the new agents.
3. Identify the most important adverse events and other risks of the new therapeutic agents.
4. State the route of administration for each new drug and the most important considerations regarding dosage and administration.
5. Compare the new therapeutic agents with older medications to which they are most similar in properties and/or use, and identify the most important advantages and disadvantages for the new drugs.

Activity type: Knowledge-based

Target Audience: Pharmacists and Pharmacy Technicians

Learning level: 1

Accreditation Information

The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  This activity is approved for 2.0 contact hours of CPE credit (0.20 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-17-229-H01-P/T.

To obtain credit for "New Therapeutic Agents Marketed in 2017: Part 1," complete the assessment with a grade of 70% or better, both evaluations, and CLAIM credit. Participants will need to have a valid pharmacist.com username and password to claim credit. After your credit has been claimed, please visit CPE monitor for your transcript.

APhA continuing pharmacy education policy provides you with two opportunities to successfully complete this continuing pharmacy education assessment. Please note that the questions may not appear in the same order as printed and you will not be permitted to submit the assessment a third time. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.

Initial release date: September 1, 2017
Expiration date: September 1, 2020 - NO CREDIT GRANTED AFTER THIS DATE

Development

"New Therapeutic Agents Marketed in 2017: Part 1” is a home-study continuing education activity for pharmacists and pharmacy technicians developed by the American Pharmacists Association.

Authors

Daniel A. Hussar, PhD, FAPhA

Remington Professor of Pharmacy, University of the Sciences College of Pharmacy

600 S. 43rd St., Philadelphia, PA 19104-4495

d.hussar@usciences.edu

Terra L. Hussar, MD

Department of Neurology, Hershey Medical Center

Hershey, PA

Advisory Board

Mark S. Johnson, PharmD, BCPS

Professor, Department of Pharmacy Practice and Director of Postgraduate Education, Bernard J. Dunn School of Pharmacy

Shenandoah University, Winchester, VA

Disclosures

Mark S. Johnson, PharmD, BCPS declares that he and his spouse hold stock in Merck & Co., Inc.

Daniel A. Hussar, PhD, FAPha; Terra L. Hussar, MD; and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For complete staff disclosures, please see the Education and Accreditation Information section at www.pharmacist.com/apha-disclosures.

Fee

There is no fee associated with this activity for members of the American Pharmacists Association. There is a $25 fee for nonmembers.

System Requirements

Computer and Internet access is required to complete this activity.  Please visit our website to view the Technology System Requirements to have a positive learning experience.

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE# 0202-0000-17-229-H01-P 0.2 CEUs September 01, 2017 - September 01, 2020
ACPE# 0202-0000-17-229-H01-T 0.2 CEUs September 01, 2017 - September 01, 2020